Poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) (PCL-PEG-PCL) nanoparticles for honokiol delivery in vitro.
In this article, poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) (PCL-PEG-PCL, PCEC) nanoparticles were successfully prepared for honokiol delivery in vitro. Blank or honokiol loaded PCL-PEG-PCL nanoparticles were prepared in moderate condition by solvent diffusion method without using any surfactants. The prepared blank PCL-PEG-PCL nanoparticles are mono-dispersed and smaller than 200 nm. The particle size increased with increase in polymer concentration and oil-water (O/W) ratio. The prepared PCL-PEG-PCL nanoparticles (40 mg/mL, ca. 106 nm) did not induce hemolysis in vitro. And the 50% inhibiting concentration (IC50) of it (48 h) on HEK293 cells was higher than 5 mg/mL. Honokiol could be efficiently loaded into PCL-PEG-PCL nanoparticles and released from these nanoparticles in an extended period in vitro. After honokiol (HK) was entrapped into PCL-PEG-PCL nanoparticles, the particle size increased with the increase in HK/PCEC mass ratio in feed, and the encapsulated honokiol retained potent anticancer activity in vitro. The PCL-PEG-PCL nanoparticle was suitable for honokiol delivery, and such honokiol loaded PCL-PEG-PCL nanoparticle was a novel honokiol formulation.
Gou
MaLing
M
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, People's Republic of China.
Zheng
Lan
L
Peng
XinYun
X
Men
Ke
K
Zheng
XiuLing
X
Zeng
Shi
S
Guo
Gang
G
Luo
Feng
F
Zhao
Xia
X
Chen
LiJuan
L
Wei
YuQuan
Y
Qian
ZhiYong
Z
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D001713:Biphenyl Compounds / Q000008:administration & dosage*; D002460:Cell Line; D045744:Cell Line, Tumor; D004337:Drug Carriers / Q000737:chemistry; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D005260:Female; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D017705:Lignans / Q000008:administration & dosage*; D053758:Nanoparticles; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology; D010316:Particle Size; D011091:Polyesters / Q000737:chemistry*; D011092:Polyethylene Glycols / Q000737:chemistry*; D011817:Rabbits; D012997:Solvents / Q000737:chemistry; D000498:Allyl Compounds; D010636:Phenols
D000972:Antineoplastic Agents, Phytogenic; D001713:Biphenyl Compounds; D004337:Drug Carriers; D004365:Drugs, Chinese Herbal; D017705:Lignans; D011091:Polyesters; D011092:Polyethylene Glycols; D012997:Solvents; C492324:poly(epsilon-caprolactone)-poly(oxyethylene)-poly(epsilon-caprolactone); C005499:honokiol; D000498:Allyl Compounds; D010636:Phenols